RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUPSTUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWINGTREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTSWITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE
Sponsor: Pfizer/Merck
Protocol number: MK-8835/PF-04971729
Projected enrollment dates: June 2014
Official study title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE